LGC Acquires Technopath Clinical Diagnostics to Strengthen Position in Clinical Diagnostics QC Market
By LabMedica International staff writers Posted on 03 Feb 2021 |
Illustration
LGC (Middlesex, UK) has acquired Technopath Clinical Diagnostics (Tipperary, Ireland), a developer and manufacturer of quality control (QC) solutions for clinical laboratories.
Technopath Clinical Diagnostics’ QC and software products are used by laboratories in over 120 countries globally. The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.
“We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC,” said Euan O’Sullivan, President & Chief Operating Officer, LGC. “Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”
“We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit,” added Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics. “Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Related Links:
LGC
Technopath Clinical Diagnostics
Technopath Clinical Diagnostics’ QC and software products are used by laboratories in over 120 countries globally. The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.
“We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC,” said Euan O’Sullivan, President & Chief Operating Officer, LGC. “Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”
“We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit,” added Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics. “Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”
Related Links:
LGC
Technopath Clinical Diagnostics
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics